• Grand Pharmaceutical announced Nov. 10, 2026, that its Phase II trial in China of migraine-prevention treatment GPN01020 enrolled its first patient.
• The placebo-controlled study plans to enroll 180 patients to evaluate the innovative traditional Chinese medicine's efficacy, safety and tolerability.
• Previously reported investigator-initiated studies showed favorable efficacy and safety, with fewer migraine attacks and improved symptoms.
• The trial supports expansion beyond ear, nose and throat treatments into neurological chronic diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261110-12406795), on November 10, 2026, and is solely responsible for the information contained therein.